switching from retatrutide to tirzepatide How to Switch Between Retatrutide and Tirzepatide (Without Screwing It Up) How Is Retatrutide Compared to

PMID 9849822

WEDNESDAY, July 23, 2025 (HealthDay News) -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk

It is unclear whether those involved in the study were prescribed the medication for diabetes or obesity

Trimi's disclosure of a state board license number gives you a concrete verification step you can actually take

has grown 49% over six months, from 90,500 monthly searches in September 2025 to over 135,000 by February 2026

Report Scope and Glucagon-Like Peptide 1 (GLP-1) Agonists Market Segmentation Glucagon-Like Peptide 1 (GLP-1) Agonists Market Trends Trend: Expanding Use of GLP-1 Agonists for Obesity Management and Cardiometabolic Health The Glucagon-Like Peptide 1 (GLP-1) Agonists Market is witnessing a major transformation as these therapies expand beyond diabetes management into obesity treatment and broader cardiometabolic care